Creative Bio of Guangzhou Raises $90 Million for Oncology Tests

reative Biosciences, a Guangzhou oncology testing company, raised $90 million in a  Series C funding led by Tsing Song Capital. In 2018, Creative Bio was approved by China's NMPA to market Colosafe, a stool-based diagnostic test for colon cancer. The company says Colosafe costs less than half the US competition but has a higher detection specificity. Creative was founded by the research team led by Professor Hongzhi Zou at Sun Yat-sen University. It will use the proceeds to develop early screening and point-of-care testing products for lung, bladder, liver and cervical cancers. More details.... Share this with colleagues: // //